DURICEF CAPSULE

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

CEFADROXIL

から入手可能:

BRISTOL-MYERS SQUIBB CANADA

ATCコード:

J01DB05

INN（国際名）:

CEFADROXIL

投薬量:

500MG

医薬品形態:

CAPSULE

構図:

CEFADROXIL 500MG

投与経路:

ORAL

パッケージ内のユニット:

100

処方タイプ:

Prescription

治療領域:

FIRST GENERATION CEPHALOSPORINS

製品概要:

Active ingredient group (AIG) number: 0115958005; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2009-02-05

製品の特徴

PRODUCT MONOGRAPH
PR DURICEF*
(CEFADROXIL)
CAPSULES, 500 MG
ANTIBIOTIC
Bristol-Myers Squibb Canada
Date of Preparation:
2365 Cote de Liesse
October 25, 2004
St. Laurent PQ
H4N 2M7
Control#: 094706
*
TM of Bristol-Myers Squibb Company used
under licence by Bristol-Myers Squibb Canada
1
PRODUCT MONOGRAPH
DURICEF*
(CEFADROXIL)
Capsules, 500 mg
THERAPEUTIC CLASSIFICATION
ANTIBIOTIC
ACTION AND CLINICAL PHARMACOLOGY
DURICEF (cefadroxil) is a cephalosporin with bactericidal activity.
_In vitro_ studies have shown
that the antibacterial activity of the cephalosporins results from
their ability to inhibit
mucopeptide synthesis in the bacterial cell wall.
INDICATIONS AND CLINICAL USE
DURICEF (cefadroxil) may be indicated for the treatment of the
following infections when
caused by susceptible strains of the organisms indicated:
-
Acute uncomplicated urinary tract infections when caused by _E. coli_,
Klebsiella species and
some strains of _Proteus mirabilis_.
-
Skin and skin structure infections caused by _Staphylococcus aureus_
and/or group A beta-
hemolytic streptococci.
-
Acute pharyngitis-tonsillitis, when caused by group A beta-hemolytic
streptococci.
-
Lower respiratory tract infections, including pneumonia, caused by _S.
pneumoniae (D._
_pneumoniae), S. Pyogenes_ (Group A-beta hemolytic streptococci), _K.
pneumoniae_ and _S._
_aureus_.
Appropriate bacteriological studies should be performed prior to and
during therapy in order to
identify and determine the susceptibility of the causative
organism(s).
CONTRAINDICATIONS
DURICEF (cefadroxil) is contraindicated in patients with a known
hypersensitivity to the
cephalosporin group of antibiotics or to any component of the
formulation.
WARNINGS
Before therapy with DURICEF is instituted, careful inquiry should be
made to determine whether
the patient has had previous hypersensitivity reactions to DURICEF,
other cephalosporins,
penicillins, or other drugs. If this product is to be given to
penicillin-sensitive patients, caution
should be exercised because cross-sensitivity am